adenine has been researched along with Cytokine Release Syndrome in 1 studies
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geyer, MB | 1 |
| Rivière, I | 1 |
| Sénéchal, B | 1 |
| Wang, X | 1 |
| Wang, Y | 1 |
| Purdon, TJ | 1 |
| Hsu, M | 1 |
| Devlin, SM | 1 |
| Palomba, ML | 1 |
| Halton, E | 1 |
| Bernal, Y | 1 |
| van Leeuwen, DG | 1 |
| Sadelain, M | 1 |
| Park, JH | 1 |
| Brentjens, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19[NCT00466531] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2007-03-21 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for adenine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Topics: Adenine; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2019 |